ONCY will wait until Feb options expire before facing the music. For all you cheerleaders, although (almost) everyone thinks PFS data will be the next release, the company never said that. You can read the transcripts yourself. They already have PFS data and it's bad, but they can wait until they have OS data, which they have too. After all, half the patients have been on trial for 10 months and the other for 6. Take it to the bank, more than 84 are dead. If you're Catholic, a few Hail Mary's and Acts of Contrition may help (in the short term)
What seems clear is:
- There's stabilization
- There's tumor shrinkage
- There's little to no side effects
- That if we have had a family die of cancer, we are hopeful for ONCY's science
- That time will tell in terms of FDA approval
- There's 75% BS on this board
- The rest provides good information that helps us evaluate ONCY as a good or bad investment
You got that right but the crux of the matter is in determining which 75%-- Maybe cheerleading #$%$ like armed escape or anally fixated kenny are telling you what you want to hear. As for tumor shrinkages etc. You are a just a fool. The tumor shrinkage (if any) is related to the chemo not REO and that point is about to be made rudely evident to you in very short order.
As I and others have commented before, for posts such as this from rational_whatever and others, click on their identity and have a look at what they have been up to on a variety of boards, and then draw your own conclusions on their latest "thoughts".
I assume you mean blinded but whatever. I'm stating that I believe they have the info right now, most likely on both PFS and OS and are busy massaging the data, conferring with the FDA and preparing the speech to present the data in the most misleading, but technically accurate manner using any attempt to salvage the program. But I think it highly likely the trial will fail and the company has given repeated signals that it will fail, but the acolytes remain faithful (belief without evidence). But that is the norm--more cancer trials fail than succeed.
You could do the math on the statsig tumor resposne data ( I did) and see how much wiggle room ONCY has for the tumor response data to translate into statsig PFS and OS numbers.